Company Overview and News

 
Change in substantial holding

2016-05-09 asx.com.au

 
Appendix 4C - quarterly

2016-04-28 asx.com.au

 
The Zacks Analyst Blog Highlights: Actelion, Mesoblast, Kindred Biosciences and CorMedix

2016-04-04 zacks
Chicago, IL – April 04, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Actelion Ltd. (ALIOF - Snapshot Report), Mesoblast Limited (MESO - Snapshot Report), Kindred Biosciences, Inc. (KIN - Snapshot Report) and CorMedix, Inc.

 
4 Best Biotech Stocks of the First Quarter of 2016

2016-04-01 zacks
If u soar high and high, what happens? You come tumbling down. The same holds true for the biotech sector which had a hellish second-half 2015 after a heady bull run. And the picture of the first quarter of 2016 is no different either with the NASDAQ Biotechnology Index declining 20.4% year to date. Biotech majors like Amgen Inc. (AMGN - Analyst Report) and Gilead Sciences Inc. (GILD - Analyst Report) among others are weighing heavily on the index with their share prices falling sharply year to date.

 
Appendix 3B

2016-02-26 asx.com.au

 
GVHD Product Launched In Japan

2016-02-24 asx.com.au

 
MESOBLAST Form EX-99.1

2016-02-17 sec.gov
EX-99.1 Exhibit 99.1      MESOBLAST CELL THERAPY SHOWS CLINICAL BENEFIT IN FIRST COHORT OF PATIENTS WITH BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS New York; USA; and Melbourne, Australia; 16 February 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), today announced results from the first cohort of its ongoing Phase 2 trial in rheumatoid arthritis (RA) patients who have previously failed one or more biologic agents.

 
MESOBLAST Form 6-K (Current Report of Foreign Issuer)

2016-02-17 sec.gov
Form 6-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Form 6-K     Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of February 2016 Commission File Number 001-37626     Mesoblast Limited (Exact name of Registrant as specified in its charter)     Not Applicable (Translation of Registrant’s name into English) Australia (Jurisdiction of incorporation or organization) Silviu Itescu Chief Exe

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...